S-1: Semnur Pharma Files S-1, Details SP-102 & Financial Woes

Semnur Pharmaceuticals filed an S-1 registration statement, outlining its non-opioid pain product SP-102's development, recent business combination, and significant financial challenges including a going concern doubt.

Summary

• Semnur Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on non-opioid pain management, with its lead product candidate being SP-102 (SEMDEXA) for sciatica.
• SP-102 has received Fast Track designation from the FDA and, if approved, could be the first FDA-approved epidural steroid injection for sciatica.
• A pivotal Phase 3 CLEAR-1 trial for SP-102 completed in March 2022 showed statistically significant and clinically meaningful improvements in pain and disability.
• The FDA, however, requested a confirmatory Phase 3 CLEAR-2 trial for SP-102 due to risks associated with interventional procedures and the lack of existing FDA-approved ESIs for sciatica, requiring a larger safety database and repeat injection efficacy evidence.
• The CLEAR-2 trial is expected to commence in the second half of 2025 and complete by mid-2026, pushing the targeted commercial launch of SP-102 to the second half of 2027.
• Semnur consummated a business combination with Denali Capital Acquisition Corp. on September 22, 2025, and is now Semnur Pharmaceuticals, Inc.
• The company reported net losses of $4.7 million in 2024, $3.3 million in 2023, $1.7 million for the first six months of 2025, and $2.6 million for the first six months of 2024.
• As of June 30, 2025, Semnur had an accumulated deficit of $117.0 million and cash and cash equivalents of $55,000.
• Semnur is highly dependent on its parent company, Scilex Holding Company, for services and funding, with Scilex controlling approximately 82% of Semnur's voting power.
• A Securities Purchase Agreement (Biconomy SPA) was signed on September 23, 2025, with Biconomy PTE.LTD for 6,250,000 shares at $16.00 per share, payable in Bitcoin, but the closing has not yet occurred.
• The company's securities were delisted from Nasdaq and now trade on the Pink Limited Market of the OTC Markets.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, evidenced by recurring significant losses, negative cash flow, and an accumulated deficit of $117.0 million with only $55,000 in cash, leading to substantial doubt about its ability to continue as a going concern. Its sole product candidate, SP-102, faces significant regulatory delays with the FDA requiring a confirmatory Phase 3 trial, pushing potential commercial launch to late 2027. The recent delisting from Nasdaq further highlights operational and financial instability. While a business combination and potential capital raises are noted, the reliance on highly volatile Bitcoin for a significant capital raise introduces additional, untested risks. The overall risk profile is extremely high, making the stock a strong sell.

Positives

• SP-102 has received Fast Track designation from the FDA, which may expedite the development and regulatory review process.
• If approved, SP-102 has the potential to be the first FDA-approved epidural steroid product for sciatica, offering a significant market advantage.
• The Phase 3 CLEAR-1 trial demonstrated statistically significant and clinically meaningful reductions in pain intensity and improvements in disability index scores for sciatica patients.
• SP-102's formulation is designed without neurotoxic preservatives or particulates, potentially offering a safer alternative to current off-label ESI products.
• The company plans to leverage Scilex's established commercial infrastructure, including a sales force of over 70 representatives, for SP-102's commercialization.
• The management team possesses extensive experience in biopharmaceutical development and commercialization, with a track record of success in the pain and neurology markets.
• SP-102 benefits from long-term patent protection (expiring in 2036) and technical barriers to entry for potential competitors due to its novel formulation and manufacturing process.

Negatives

• The company has a limited operating history and has incurred significant net losses since its inception, with an accumulated deficit of $117.0 million as of June 30, 2025.
• Semnur has only one product candidate, SP-102, no products approved for commercial sale, and has not generated any revenue from product sales.
• The FDA requested a confirmatory Phase 3 CLEAR-2 trial for SP-102, indicating that the data from the initial CLEAR-1 trial was insufficient for approval, leading to delays and increased costs.
• The company's cash and cash equivalents were only $55,000 as of June 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• Semnur is substantially dependent on its parent company, Scilex, for services and funding, and Scilex's controlling interest (approximately 82% voting power) may lead to conflicts of interest.
• Material weaknesses in internal control over financial reporting were identified for the years ended December 31, 2023 and 2022.
• The company's securities were delisted from Nasdaq and now trade on the Pink Limited Market of the OTC Markets, potentially impacting liquidity and investor confidence.
• The Biconomy SPA, involving payment in Bitcoin, introduces significant volatility and regulatory risks related to cryptocurrency, an untested treasury strategy for the company.

Risks

• Recurring losses from operations, negative cash flows, and substantial cumulative net losses raise substantial doubt about the company's ability to continue as a going concern.
• The company is substantially dependent on the success of its only product candidate, SP-102, and its ability to complete development, obtain approval, and commercialize it.
• Reliance on sole or single-source suppliers and manufacturers for SP-102 and raw materials poses risks of supply disruptions and non-compliance with FDA regulations.
• Dependence on third parties to conduct clinical trials introduces risks of contractual failures, non-compliance, and missed deadlines.
• Delays in clinical trials could result in increased costs and delay the ability to obtain commercial approval and generate revenue.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable, with no guarantee of approval or approval for broad indications.
• Difficulty in enrolling or maintaining patients in clinical trials could delay or prevent further development.
• Market opportunities for product candidates may be smaller than estimated, or approvals may be for narrower patient populations.
• Significant competition from larger biotechnology and pharmaceutical companies with greater resources and experience.
• Failure to attain significant market acceptance of SP-102, if approved, among physicians, patients, and healthcare payers.
• Uncertainty regarding third-party payor coverage and adequate reimbursement for newly approved products.
• Results of preclinical studies and early clinical trials may not be predictive of future clinical trial success, and current trials are limited in scope.
• SP-102 is complex and difficult to manufacture, with potential for delays, supply limitations, or manufacturing problems.
• Inability to retain key executives may delay development efforts and harm business.
• Challenges in managing company growth effectively as it expands.
• Risk of product liability lawsuits, which could incur substantial liabilities or limit commercialization.
• Disruptions in research and development facilities due to natural disasters or other events could adversely affect operations.
• Inability to maintain patent protection for product candidates or if the scope of protection is not sufficiently broad.
• Intellectual property rights being invalidated or circumvented.
• Confidentiality agreements with employees may not adequately prevent disclosure of trade secrets.
• Claims challenging the inventorship or ownership of patents and other intellectual property.
• Claims of infringement, misappropriation, or violation of third-party intellectual property rights.
• Inability to protect intellectual property rights throughout the world due to varying patent laws.
• Changes in patent laws or patent jurisprudence could diminish the value of patents.
• Failure to obtain patent term extension and data exclusivity for product candidates.
• Failure to comply with health and data protection laws and regulations could lead to enforcement actions and penalties.
• Impact of actions by the new Trump administration, including executive orders, policies, new legislation, and judicial decisions, on business operations and regulatory agencies.
• Risks associated with the use of hazardous materials and compliance with environmental laws.
• Misconduct or improper activities by employees, independent contractors, consultants, commercial partners, and vendors.
• Healthcare reform measures could hinder or prevent product candidates' commercial success.
• Failure to obtain prior FDA authorization for proposed product brand names.
• Changes in funding for the FDA could hinder its ability to review and approve new products.
• Actual or potential conflicts of interest due to overlapping directors and officers with Scilex.
• Historical financial statements may not be indicative of standalone operations, and the company will incur incremental costs as a stand-alone public company.
• Scilex's control over the company, with interests that may differ from those of public shareholders.
• Series A Preferred Stock held by Scilex has rights, preferences, and privileges preferential to common stockholders.
• Future sales, or the perception of future sales, of a substantial number of shares of common stock may cause the price to decline.
• No cash dividends expected in the foreseeable future, limiting return on investment to capital appreciation.
• Operating results may fluctuate significantly on a quarterly or annual basis.
• Cash and cash equivalents could be adversely affected if financial institutions fail.
• Lack of research or adverse opinions from securities analysts could cause stock price and trading volume to decline.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to product candidates.
• Limitations on the ability to use net operating loss and tax credit carryforwards.
• If estimates or judgments relating to critical accounting policies are based on incorrect assumptions, operating results could fall below expectations.
• Anti-takeover provisions in the Charter and Bylaws and under Delaware law could make an acquisition more difficult.
• Designation of the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation and federal district courts for Securities Act claims could limit stockholders' ability to obtain a favorable judicial forum.
• Reduced reporting requirements as an emerging growth company may make common stock less attractive to investors.
• Controlled company status may lead to reliance on exemptions from certain corporate governance requirements.
• Increased costs as a result of operating as a public company and substantial management time devoted to compliance initiatives.
• Inability to satisfy initial listing requirements and other rules of Nasdaq could negatively impact the price of securities.
• The price of Bitcoin, in which the company intends to invest proceeds from the Biconomy SPA, is highly volatile, which could cause the company's share price to fluctuate significantly.
• The company's cryptocurrency treasury strategy has not been implemented or tested and may prove unsuccessful.
• If digital assets held are classified as a security, the company may be subject to extensive regulation, resulting in significant costs or cessation of operations.
• The emergence or growth of other digital assets could negatively impact the price of cryptocurrencies held.
• Lack of legal recourse and insurance for digital assets increases the risk of total loss in the event of theft or destruction.
• The irreversibility of digital asset transactions exposes the company to risks of theft, loss, and human error.
• Security breaches or cyberattacks on cryptocurrency holdings, or loss/destruction of private keys, could lead to loss of cryptocurrency.
• Custodially-held cryptocurrencies may become part of the custodian's insolvency estate in bankruptcy proceedings.

Future Outlook

The company plans to commence the confirmatory Phase 3 CLEAR-2 trial for SP-102 in the second half of 2025, with an expected completion by mid-2026. This timeline aims for a 505(b)(2) NDA submission to the FDA and a targeted commercial launch of SP-102 in the second half of 2027. The company also intends to expand its product portfolio by developing or acquiring non-opioid assets and will leverage Scilex's commercial infrastructure during a three-year transition period to build its own capabilities.

Management Comments

• Our guiding principle has always been and remains a patient-first approach, which drives our mission to meet the increasing global demand for more effective and safer non-opioid pain management solutions.
• We believe we are on the cusp of establishing Semnur as the preeminent name in commercial non-opioid pain management, specifically targeting the unmet needs in both acute and chronic pain sectors with our innovative and leading therapies.
• We believe that we have made substantial progress in demonstrating the rapid onset and enhanced tolerability of our product candidate.
• We expect the clinical benefit of SP-102 to last up to approximately 100 days.
• Our reimbursement team will file for a separate J code for SP-102. Once a product receives a special J code, customers will be reimbursed for the product. We have experienced account executives who will follow the process to file for the special J code prior to the launch, which we expected to be granted within two to three quarters after launch.

Industry Context

The company operates in the highly competitive and rapidly advancing biotechnology and pharmaceutical industries, specifically within the non-opioid pain management market. This sector is driven by a growing demand for effective and safer alternatives to traditional pain medications, particularly opioids, and aims to address high unmet medical needs. SP-102 is positioned to potentially be the first FDA-approved epidural steroid injection for sciatica, differentiating it from existing off-label treatments that carry significant safety warnings. The industry is also influenced by evolving regulatory landscapes, such as FDA requirements for clinical trial diversity and increased scrutiny on promotional claims, as well as cost containment pressures from healthcare payors.

Comparison to Industry Standards

• SP-102, if approved, has the potential to become the first FDA-approved epidural steroid product for the treatment of sciatica, distinguishing it from currently used off-label particulate steroids (e.g., methylprednisolone acetate, triamcinolone acetonide, betamethasone sodium phosphate/acetate) which carry FDA class warnings for serious neurologic complications.
• The efficacy results of the CLEAR-1 trial for SP-102 (ITT: -0.52 NPRS difference; mITT: -1.08 NPRS difference) and standardized effect sizes (ITT: 0.28; mITT: 0.68) are comparable to or greater than those observed for other clinically meaningful analgesics for chronic low back pain (median group mean difference: 0.7-points; SES: 0.32) and off-label ESIs (median group mean difference: 0.49; SES: 0.29).
• The expected clinical benefit duration of SP-102 (up to approximately 100 days) is anticipated to be longer than currently used off-label dexamethasone formulations, which are generally believed to provide pain relief for a shorter period.

Management Changes

Corporate Governance

Legal Proceedings

• Not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on the business.
• The company may become involved in various legal proceedings in the ordinary course of business, including matters involving employment, intellectual property, or effects from the use of therapeutics utilizing its technology.

Related Party Transactions

• **Transition Services Agreement (September 22, 2025)**: Scilex Holding Company provides administrative, financial, legal, tax, insurance, facility, information technology, and other services to Semnur for a three-year term on a cost-plus 10% basis, with service fees not exceeding $2.0 million per annum until the Oramed Note is fully repaid.
• **Sponsor Support Agreement (August 30, 2024)**: The Sponsor and Denali's directors/executive officers agreed to vote in favor of the Business Combination and related matters, and against competing proposals.
• **Company Stockholder Support Agreement (August 30, 2024)**: Scilex (as the sole stockholder of Legacy Semnur) agreed to vote in favor of the Merger Agreement and Business Combination.
• **Sponsor Interest Purchase Agreement (SIPA) (August 30, 2024)**: Scilex purchased 500,000 Class B ordinary shares from the Sponsor for $2.0 million cash and 300,000 Scilex shares (adjusted to 8,571 shares after reverse stock split). The payment for Scilex shares was later settled in cash ($213,932.16).
• **Sponsor Promissory Notes**: Includes Convertible Promissory Note 1 (issued April 11, 2023, amended to a total principal amount up to $2.0 million as of January 24, 2025, with $1,574,970 outstanding as of June 30, 2025) and Convertible Promissory Note 2 (issued July 10, 2024, for up to $180,000, with $15,037 outstanding as of June 30, 2025), both issued to the Sponsor.
• **Extension Scilex Convertible Promissory Note (August 9, 2024)**: Issued to Scilex for up to $180,000. Scilex deposited an aggregate of $123,107 into the Trust Account as of June 30, 2025, and an additional $1,750 from July-August 2025 for extensions.
• **Debt Exchange Agreement (August 30, 2024)**: Scilex contributed $54,236,058 of outstanding indebtedness owed by Legacy Semnur in exchange for 5,423,606 shares of Series A Preferred Stock and 542,361 shares of New Semnur Common Stock upon the Business Combination.
• **Oramed Note (September 21, 2023, amended)**: Scilex issued a senior secured promissory note to Oramed Pharmaceuticals Inc. for $101,875,000, with the maturity date extended to December 31, 2025. Semnur was a guarantor but was released from this obligation upon the Business Combination.
• **Executive Employment Agreements (September 22, 2025)**: New employment agreements were made effective for Jaisim Shah (CEO & President), Henry Ji, Ph.D. (Executive Chairperson), and Stephen Ma (CFO, SVP & Secretary), with increased annualized salaries and target bonuses.
• **Stock Option Grants (August 30, 2024)**: Non-statutory Stock Options (NSOs) to purchase an aggregate of 40,000,000 shares were approved for grant to executive team members and certain Scilex employees, with an exercise price of $1.27 per share, vesting over four years, but exercisability is contingent on the Oramed Note repayment and Option Exchange approval.
• **Consulting Agreements with Stock Remuneration (August 25/26, 2024, amended July 22, 2025)**: Agreements with 450W42ND MIMA, LLC (3.2 million shares), Wise Orient Investments Limited (3.2 million shares), and JW Investment Management Company Limited (8.0 million shares) for consulting/advisory services, payable in Semnur Common Stock upon the Business Combination.
• **Stock Issuance Agreement (July 22, 2025)**: 10,000,000 shares of Semnur Common Stock were issued to a law firm as a retainer for legal services and payment for prior services.

Stakeholder Impact

• **Shareholders**: Face potential significant dilution from warrant exercises and future capital raises. Scilex's controlling interest (82% voting power) may limit the influence of public shareholders on corporate decisions. The delisting from Nasdaq and trading on the OTC Markets could negatively impact liquidity and the market price of shares. The high volatility and regulatory uncertainty of the cryptocurrency treasury strategy introduce additional risks to shareholder value.
• **Employees**: Executive officers have new employment agreements with increased compensation and stock option grants, providing long-term incentives, though exercisability is contingent on certain financial conditions. The company's financial instability and going concern doubt could impact job security and future compensation for all employees.
• **Customers/Patients**: The development of SP-102 offers the potential for a new FDA-approved non-opioid treatment for sciatica, which could provide a safer and more effective option for patients suffering from acute and chronic pain, potentially reducing reliance on off-label or opioid therapies.
• **Suppliers/Creditors**: The company's dependence on single-source suppliers for SP-102 components creates supply chain risks. The Oramed Note, while primarily Scilex's obligation, has indirect implications for Semnur's financial stability and access to funding. The company's going concern doubt may make it challenging to secure favorable terms from future creditors or suppliers.
• **Regulatory Bodies**: The company faces ongoing scrutiny from the FDA regarding its clinical trials and product approvals, as well as from other regulatory agencies concerning compliance with healthcare, data protection, and anti-corruption laws. Identified material weaknesses in internal controls require remediation efforts.

Next Steps

• Commence the confirmatory Phase 3 CLEAR-2 trial for SP-102 in the second half of 2025.
• Complete the CLEAR-2 trial by mid-2026.
• Submit a 505(b)(2) NDA to the FDA for SP-102 approval.
• Target commercial launch of SP-102 in the second half of 2027.
• File for a separate J-code for SP-102 prior to launch.
• Develop internal commercial infrastructure and other business functions during the three-year transition period with Scilex.
• Increase full-time employees to strengthen R&D, general administrative, manufacturing, regulatory, and commercial functions.
• Continue discussions with Sanofi S.A. and identify/certify new suppliers for sodium hyaluronate.
• Engage Lifecore for commercial production of SP-102, if approved.
• Initiate negotiations with national insurance companies, Medicare, and Medicaid to secure inclusion of SP-102 in their programs.
• Enter into a distribution agreement with a major third-party logistics provider for SP-102.
• Evaluate opportunities to develop or acquire non-opioid assets.
• Implement remediation measures for identified material weaknesses in internal control over financial reporting.
• Seek additional financing through equity offerings, debt financings, collaborations, government contracts, or other strategic transactions.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by recurring significant losses, negative cash flow, and an accumulated deficit of $117.0 million with only $55,000 in cash, leading to substantial doubt about its ability to continue as a going concern. Its sole product candidate, SP-102, faces significant regulatory delays with the FDA requiring a confirmatory Phase 3 trial, pushing potential commercial launch to late 2027. The recent delisting from Nasdaq further highlights operational and financial instability. While a business combination and potential capital raises are noted, the reliance on highly volatile Bitcoin for a significant capital raise introduces additional, untested risks. The overall risk profile is extremely high, making the stock a strong sell.

Keywords

Semnur Pharmaceuticals, SP-102, SEMDEXA, non-opioid pain management, sciatica, epidural steroid injection, FDA Fast Track, biopharmaceutical, clinical trials, SEC filing, S-1, Scilex Holding Company, Bitcoin, cryptocurrency treasury, pain relief, drug development, regulatory approval, biotech, pharmaceuticals